3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
1
Interventions
Injections
54
Cisplatin
49
Paclitaxel
48
Carboplatin
43
Gemcitabine
38
pembrolizumab
36
Docetaxel
36
Capecitabine
36
Drug Therapy
34
anlotinib
25
Bevacizumab
25
Fluorouracil
24
Cyclophosphamide
24
icotinib
23
Oxaliplatin
20
fludarabine
19
Pemetrexed
17
Leucovorin
16
Irinotecan
16
Temozolomide
14
Nivolumab
14
Doxorubicin
14
Cetuximab
14
camrelizumab
13
apatinib
13
Trastuzumab
12
Rituximab
11
Fulvestrant
11
Etoposide
11
tesetaxel
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
INDUSTRY
×
talactoferrin alfa
×
Clear all
NCT00706862
2012-03-15
FORTIS-C
Agennix
Phase 3
Unknown
1,100 enrolled